UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of earliest event reported):
February
25, 2019
CHEMED CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware |
1-8351 |
31-0791746 |
(State or other jurisdiction of incorporation) |
(Commission File Number)
|
(I.R.S. Employer Identification Number) |
2600 First Financial Center, 255 East 5th Street, Cincinnati, OH45202 |
(Address of principal executive offices) (Zip Code) |
Registrant’s
telephone number, including area code:
(513) 762-6690
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ⃞
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ⃞
Page 1 of 2
Item 8.01 Other Events
On February 25, 2019, Chemed Corporation issued a press
release announcing that on February 22, 2019, its Board of Directors
increased the authorization of Chemed’s share repurchase program to
provide for $150 million of future share repurchases. These will be
funded through a combination of cash generated from operations as well
as utilization of its revolving credit facility. A copy of the release
is furnished herewith as Exhibit 99.
Item
9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CHEMED CORPORATION |
|||||
|
|||||
Dated: |
February 25, 2019 |
By: |
/s/ Michael D. Witzeman |
||
Michael D. Witzeman |
|||||
Vice President and Controller |
Page 2 of 2